官政燕,郑璐璐,方晗,孙泽琳,裴志芳,刘凤姣,邹隽麟,吴婷婷,钟旭,陈晓彬

• 1:中南大学湘雅医院心内科
• 2:中南大学湘雅医院心脏超声室

摘要(Abstract)：

目的 比较Cardi-O-fix卵圆孔未闭（PFO）封堵器和国产房间隔缺损封堵器（ASDO治疗PFO合并房间隔瘤（ASA）的有效性及安全性。方法 回顾性分析2019年1月至2020年12月在中南大学湘雅医院心内科行经导管介入封堵治疗的70例PFO合并ASA患者，根据PFO解剖结构特点选用Cardi-O-fix PFO封堵器（COF组，共38例）或ASDO(ASDO组，共32例)行介入封堵术，术后随访12个月，比较不同封堵器的有效封堵率、残余分流、并发症发生率等指标。结果 ASDO组封堵器腰部直径（即PFO的大小）为（9.57±2.72）mm。COF组患者ASA基底部直径小于ASDO组，差异有统计学意义[经食管超声心动图：（21.46±4.87）mm比（25.09±3.68）mm,P<0.001；经胸超声心动图：（22.14±5.14）mm比（24.88±3.42）mm,P=0.010）]。随访12个月，两组患者均未发生复发性卒中或死亡事件，术后1个月、3个月、6个月和12个月的有效封堵率和残余分流率分别比较，差异均无统计学意义（均P>0.05）。两组均未发生心房颤动、心房扑动、动静脉瘘、假性动脉瘤、心包积液、心脏压塞、封堵器移位脱落等并发症。结论 对于PFO合并ASA的患者，ASDO疗效不劣于PFO封堵器。PFO合并ASA时往往PFO较大，对于基底部较小的患者，常规PFO封堵器能覆盖ASA左心房面时，建议首选常规PFO封堵器；对于ASA基底部较大的患者，常规PFO封堵器可能无法完全覆盖固定ASA，建议使用小腰大边型ASDO。

关键词(KeyWords)： 卵圆孔未闭;房间隔瘤;经导管封堵术;残余分流;并发症

Abstract:

Keywords:

基金项目(Foundation): 湖南省自然科学基金项目（S2021JJMSXM1714）

作者(Author): 官政燕,郑璐璐,方晗,孙泽琳,裴志芳,刘凤姣,邹隽麟,吴婷婷,钟旭,陈晓彬

参考文献(References)：

• [1] Calvert P, Rana B, Kydd A, et al. Patent foramen ovale:anatomy, outcomes, and closure[J]. Nat Rev Cardiol,2011, 8(3):148-160.
• [2] Pristipino C, GermonpréP, Toni D, et al. European position paper on the management of patients with patent foramen ovale. Part II-Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions[J]. Eur Heart J, 2021, 42(16):1545-1553.
• [3] Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J].N Engl J Med, 2017, 377(11):1011-1021.
• [4] Lee P, Song J, Kim J, et al. Cryptogenic stroke and high-risk patent foramen ovale:the DEFENSE-PFO trial[J]. J Am Coll Cardiol, 2018, 71(20):2335-2342.
• [5] Snijder R, Luermans J, de Heij A, et al. Patent foramen ovale with atrial septal aneurysm is strongly associated with migraine with aura:a large observational study[J]. J Am Heart Assoc,2016,5(12):e003771.
• [6] Turc G, Lee J, Brochet E, et al. Atrial septal aneurysm,shunt size, and recurrent stroke risk in patients with patent foramen ovale[J]. J Am Coll Cardiol, 2020, 75(18):2312-2320.
• [7] Deng W, Yin S, McMullin D, et al. Residual shunt after patent foramen ovale closure and long-term stroke recurrence[J]. Ann Intern Med, 2020, 173(11):946-947.
• [8] Ben-Assa E, Rengifo-Moreno P, Al-Bawardy R, et al. Eff ect of residual interatrial shunt on migraine burden after transcatheter closure of patent foramen ovale[J]. JACC Cardiovasc Interv,2020, 13(3):293-302.
• [9] Stortecky S, da Costa B, Mattle H, et al. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism:a network meta-analysis[J]. Eur Heart J, 2015, 36(2):120-128.
• [10] Zhao E, Liu W, Zhang Y, et al. Safety and effi cacy of CardiO-fix occluder for percutaneous closure of a patent foramen ovale:a single-center prospective study[J]. Medicine,2017, 96(14):e6572.
• [11] He L, Cheng G, Du Y, et al. Multidisciplinary assessment of PFO with substantial right-to-left shunting and medium-term followup after PFO device closure:a single-center experience[J]. J Interv Cardiol, 2017, 30(4):362-367.
• [12]刘文娟，张玉顺，成革胜，等.不同封堵器治疗卵圆孔未闭的有效性和安全性比较[J].中华心血管病杂志，2017, 45(6):485-490.
• [13]张玉顺，蒋世良，朱鲜阳.卵圆孔未闭相关卒中预防中国专家指南[J].心脏杂志，2021, 33(1):1-10.
• [14]徐吉喆，江尕学，刘天蕊，等.房间隔缺损或卵圆孔未闭合并房间隔瘤介入封堵治疗临床经验[J].中国介入心脏病学杂志，2021, 29(6):324-328.
• [15] Silvestry F, Cohen M, Armsby L, et al. Guidelines for the echocardiographic assessment of atrial septal defect and patent foramen ovale:from the american society of echocardiography and society for cardiac angiography and interventions[J]. J Am Soc Echocardiogr, 2015, 28(8):910-958.
• [16]中华医学会心血管内科分会，中国医师协会心血管内科分会.卵圆孔未闭预防性封堵术中国专家共识[J].中国循环杂志，2017, 32(3):209-214.
• [17] Freeman J, Woods T. Use of saline contrast echo timing to distinguish intracardiac and extracardiac shunts:failure of the3-to 5-beat rule[J]. Echocardiography, 2008, 25(10):1127-1130.
• [18] S?ndergaard L, Kasner S, Rhodes J, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J].N Engl J Med, 2017, 377(11):1033-1042.
• [19] Tobis J, Charles A, Silberstein S, et al. Percutaneous closure of patent foramen ovale in patients with migraine:the PREMIUM trial[J]. J Am Coll Cardiol, 2017, 70(22):2766-2774.
• [20] Rana B, Shapiro L, McCarthy K, et al. Three-dimensional imaging of the atrial septum and patent foramen ovale anatomy:defi ning the morphological phenotypes of patent foramen ovale[J].Eur J Echocardiogr,2010, 11(10):i19-i25.
• [21] Sorensen S, Aguilar H, McKnight W, et al. Transcranial Doppler quantifi cation of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices[J]. J Interv Cardiol, 2010, 23(6):575-580.
• [22] Lee W, Fang C, Huang C, et al. Predictors of atrial septal defect occluder dislodgement[J]. Int Heart J, 2015, 56(4):428-431.
• [23] Rovera C, Biasco L, Orzan F, et al. Percutaneous implantation of a second device in patients with residual rightto-left shunt after patent foramen ovale closure[J]. J Interv Cardiol, 2014, 27(6):548-554.
• [24]何璐，张玉顺.单中心1336例经导管封堵卵圆孔未闭患者主要并发症回顾性分析[J].中国介入心脏病学杂志，2019, 27(6):309-314.
• [25] Meier B. Iatrogenic atrial septal defect, erosion of the septum primum after device closure of a patent foramen ovale as a new medical entity[J]. Catheter Cardiovasc Interv, 2006, 68(1):165-168.